Treating Depression in Coronary Artery Disease and Chronic Heart Failure: What’s new in using Selective Serotonin Re-Uptake Inhibitors?

Author(s): Paraskevaidis Ioannis, Palios John, Parissis John, Filippatos Gerasimos, Anastasiou-Nana Maria

Journal Name: Cardiovascular & Hematological Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents

Volume 10 , Issue 2 , 2012

Become EABM
Become Reviewer
Call for Editor


Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. The presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiological mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease.

Keywords: Cardiovascular disease, chronic heart failure, citalopram, coronary artery disease, dapoxetine, depression, escitalopram, fluoxetine, fluvoxamin, paroxetine, selective serotonin re-uptake inhibitors, sertraline, vilazodone

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [109 - 115]
Pages: 7
DOI: 10.2174/187152512800388894
Price: $65

Article Metrics

PDF: 41